image credit: Unsplash

Oncomatryx announces 15m euros funding to conduct clinical trials

April 20, 2022

Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials

Oncomatryx has announced the beginning of a new phase in the development of its tumour microenvironment – targeted antibody drug conjugates (ADCs).

Phase 1 clinical trials in patients suffering metastatic solid tumours will be launched in Europe and USA in the second quarter of 2022.

Read More on Pharma Times